Cargando…
Chemotherapie ± Androgenrezeptorantagonisten beim metastasierten hormonsensitiven Prostatakarzinom
BACKGROUND: Although androgen deprivation therapy (ADT) alone has been the standard of care (SOC) in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) for decades, combination therapies of novel hormone therapy (androgen receptor-targeting agents [ARTA]) or docetaxel chemotherapy...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Medizin
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073052/ https://www.ncbi.nlm.nih.gov/pubmed/36763112 http://dx.doi.org/10.1007/s00120-023-02029-0 |